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ABSTRACT
Introduction: Epidemiological studies suggest
that statins may promote the development or
exacerbation of diabetes, but whether this
occurs through inhibition of insulin secretion
is unclear. This lack of understanding is partly
due to the cellular models used to explore this
phenomenon (cell lines or pooled islets), which
are non-physiologic and have limited clinical
transferability.
Methods: Here, we study the effect of
simvastatin on insulin secretion using
single-islet cultures, an optimal compromise
between biological observability and
physiologic fidelity. We develop and validate a
microfluidic device to study single-islet
function ex vivo, which allows for switching
between media of different compositions with a
resolution of seconds. In parallel, fluorescence
imaging provides real-time analysis of the
membrane voltage potential, cytosolic Ca2?
dynamics, and insulin release during perfusion
under 3 or 11 mM glucose.
Enhanced content The online video files are available
to view at http://www.medengine.com/Redeem/
6317F060735F7A3B.
Electronic supplementary material The online
version of this article (doi:10.1007/s13300-016-0210-y)
contains supplementary material, which is available to
authorized users.
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Results: We found that simvastatin reversibly
inhibits insulin secretion, even in high-glucose.
This phenomenon is very rapid (\60 s), occurs
without affecting Ca2? concentrations, and is
likely unrelated to cholesterol biosynthesis and
protein isoprenylation, which occur on a time
span of hours.
Conclusions: Our data provide the first
real-time live demonstration that a statin
inhibits insulin secretion in intact islets and
that single islets respond differently from cell
lines on a short time scale.
Funding: University of Padova, EASD
Foundation.
Keywords: Insulin; Islet; Microfluidic;
Simvastatin; Statin
INTRODUCTION
Statins, hydroxy-methyl-glutaryl-CoA
(HMG-CoA) reductase inhibitors, are widely used
to lower cholesterol and prevent cardiovascular
disease [1, 2]. As diabetes is characterized by high
cardiovascular risk, international guidelines
recommend that most diabetic patients should
receive statin therapy [3–5]. Statins effectively
reduce cardiovascular morbidity and mortality in
patients with diabetes [6], but epidemiological
studies suggest they increase the risk of developing
diabetes in healthy individuals [7–10] and may
worsen glycemia in diabetic patients [11].
Pathophysiologic studies in humans indicate that
statins may affect both insulin sensitivity and
insulin secretion [12]. In vitro studies show that
statins impair insulin secretion by affecting
multiple pathways [13], including cellular
cholesterol synthesis, membrane fluidity, and
isoprenylation of proteins [14]. Though their
cardiovascular benefit exceeds the diabetes
hazard [15], the mechanisms whereby statins
accelerate the onset of diabetes remain unclear,
and whether statins truly exert any action on
insulin secretion is debated [16, 17]. This is in part
because cellular models used to explore this
phenomenon, either cell lines [13, 14] or pooled
islets [14], are non-physiologic and lack clinical
transferability. Cell lines may behave differently
frommature beta cells or have incomplete glucose
sensor or insulin secretion machinery, whereas
pooled islet cultures are poorly suitable to provide
information ondynamic insulin secretion because
islet response may be heterogeneous and
asynchronous.
A single islet is the minimum fully functional
unit of the endocrine pancreas. A precise
understanding of islet response to exogenous
stimuli is better captured in vitro at the
single-islet level, devoid of complex and not
fully understood islet–islet interactions.
Microfluidics is a technology suitable for cell
culture at micrometer scale. Because a single islet
has an approximate size of 50–500 lm, it is
particularly suitable for microfluidic culture.
Accordingly, a number of microfluidic devices
have been developed for understanding single
islet behavior, as recently reviewed [18]. However
the advantages ofmicrofluidic technologygowell
beyond the size of these devices [19]. For example,
Benninger et al. used a microfluidic device to
generate precise glucose concentration gradients
in a single islet microenvironment to study
cell–cell gap junctions in the regulation of
coordinated insulin release [20]. Microfluidic
devices favor the accumulation of endogenously
secreted factors andwerepreviouslyused todetect
islet amyloid polypeptide secretion from as few as
ten islets [21] and glucose flux in live myoblasts
[22], besides insulin [23].
Here, we study the effects of simvastatin on
insulin secretion from single murine islets. A
microfluidic system able to temporally control
the single-islet soluble microenvironment is
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presented. The setup has been technically and
biologically validated, before analyzing
simvastatin action on intact isolated islets.
METHODS
Microfluidic Setup
The setup was produced by standard photo- and
soft-lithographic techniques. Details on the
fabrication of the islet culture and the
multi-inlet chips are given in the Electronic
Supplementary Material (ESM).
Animals and Pancreatic Islet Extraction
and Preparation
The protocol followed the Guide for the
Care and Use of Laboratory Animals, eighth
edition (2011) (http://grants.nih.gov/grants/
olaw/guide-for-the-care-and-use-of-laboratory-
animals.pdf), and was compliant with local
and national laws. For murine islet isolation,
we optimized a previously described protocol
[24]. Details are given in the ESM.
Microfluidic System Running Conditions
The multi-inlet microfluidic system was
connected to medium vials of different
compositions. Details are given in ESM. This
system allowed switching between up to nine
different medium compositions by remotely
controlling valve opening and closing. The
complete system is displayed in Fig. 1.
Islet Staining for Imaging of Viability,
Ca21, Membrane Potential, and Zn21
Islets were loaded with 1 mg/ml Hoechst 33342
(Sigma-Aldrich) for 10 min. PE-conjugated
Annexin-V (BD Biosciences) was added in the
perfusion medium. Prior to microfluidic device
insertion, islets were loaded with 3-lM Fura Red
acetoxymethyl (AM) (ThermoFisher) or 10 lM
Fluo-4 AM (ThermoFisher) for 50 min in RPMI
medium at 37 C for intracellular Ca2?
detection; 2-lM FluoZin-3 (ThermoFisher) was
added at the same concentration to the
different media used for islet stimulation.
Extracellular Zn2? concentration detection was
used as an indirect measure for insulin secretion
detection, as previously described [21]. To avoid
biases due to slight differences in the FluoZin-3
concentration or media autofluorescence,
before islet insertion into the microfluidic
device, a background profile using different
media was established at the beginning of
each acquisition and then subtracted to the
islet response profile. For voltage imaging, islets
were incubated for 20 min at 37 C in RPMI
with Vf2.1.Cl (200 nM, kindly provided by
Roger Y. Tsien from University of California at
San Diego) [25] and Pluronic F–127 (0.1% w/v)
(Sigma-Aldrich).
Confocal Imaging
Fluorophores were excited by light from a
460-nm LED (M470L2, Thorlabs) passing
through a T510LPXR filter (Olympus) and
directed onto the sample through a full mirror
(Chroma) while 512 fluorescence emission was
selected by a BA495-540HQ filter (Chroma). All
fluorescence images were acquired with a 209
water immersion objective (NA 0.96, Olympus)
and projected on a Complementary Metal-Oxide
Semiconductor (CMOS) cooled camera (PCO),
controlled by in-house developed software.
Image sequences of fluorescence were acquired
continuously at three frames per second with
100 ms exposure time.
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Fig. 1 Microﬂuidic setup design and validation. a Full
setup for single islet microscopy observation under
controlled dynamic biochemical stimulation. A multi-inlet
microﬂuidic chip contains a system of pneumatic valves
that are used to temporally control the medium compo-
sition entering the islet culture chamber. The pneumatic
valve system is actuated by means of electrovalves (not
shown) and is responsible for each valve opening and
closing according to the mechanism shown in c: pressur-
izing the control channel prevents medium ﬂow through
the ﬂow channel. A single islet is placed in each channel of
the islet culture microﬂuidic chip, where it is precisely
positioned because of the presence of a mechanical trap
that stops its ﬂow along the channel, as shown in c. The
islet culture microﬂuidic chip is a transparent device that is
put under the microscope for online observation. Once the
speciﬁc valve is open, medium ﬂows through the channel
because it is contained in a pressurized vial; to accurately
control its ﬂow rate, a syringe pump working in aspiration
is placed downstream of the culture system. d The system
described in a–c makes possible the biochemical stimula-
tion of a single-islet with temporal accuracy of seconds.
Medium composition is changed over time with minimal
external perturbation. e Validation of the dynamic input
system using medium with and without ﬂuorescein. The
theoretical curve (red) is compared with the actual medium
ﬂuorescence (green) detected in the region of interest
(ROI) indicated. A delay of approximately 50 s was
obtained because of the distance between the valve system
and the ROI
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Two-Photon Imaging
Two-photon acquisitions were performed with a
modular multiphoton microscope (Bergamo II,
Thorlabs) equipped with an 8-kHz resonant
scanner, extended-field-of-view collection
optics, four independent detection channels in
the backward direction, and laser-scanned Dodt
contrast in the forward direction. The
microscope was coupled to two synchronized
pulsed laser beams generated by a Ti:sapphire
pump laser (Chameleon Ultra 2, Coherent) and
an optical parametric oscillator (Camelion
Compact OPO). Two-photon microscopy at
800 nm excitation was used to visualize the
intracellular calcium (Fluo-4, green), nuclei
(Hoechst 33342, blue), and islet structure
simultaneously (transmitted light, gray).
Data Analysis
The analysis software, developed in-house in
Matlab environment (Release 14, The
MathWorks, Inc., Natick, MA, USA), was
designed to plot averaged time responses from
specific regions of interest (ROIs) as well as to
create false-color animations reporting
time-dependent fluorescence intensity
variations. False-color images were generated
using the hue-saturation-value (HSV)
visualization algorithm: hue was used to
represent fluorescence changes; saturation was
set to 1.0; the value (brightness) carried pixel
intensity from a reference image that was either
updated on a frame-by-frame basis or obtained
as an average over a specified number of frames.
The resulting frames so constructed were
converted to ordinary RGB images and
exported in the Audio Video Interlaced (AVI)
proprietary video format of Microsoft Video for
Windows applications [26]. FluoZin-3 and Fura
Red signals were analyzed independently by
playing back images in single-channel mode.
ROIs used for Fluo-4 and Fura Red signal
analysis were drawn covering the islets, while
ROIs for FluoZin-3 signal analysis were drawn
outside the islet areas. When Fura Red is excited
at 488 nm, its fluorescence emission decreases
as Ca2? concentration increases [27]. For this
reason, changes in intracellular Ca2? were
expressed as (F0/F)-1 ratios [27]. Fluo-4 and
FluoZin-3 signals were measured as relative
changes of fluorescence emission intensity: DF/
F0, where F0 is the pre-stimulus basal
fluorescence; DF = F – F0, F is fluorescence at
time t.
Compliance with Ethics Guidelines
The institutional review board of the Venetian
Institute of Molecular Medicine approved the
study. The protocol followed the Guide for the
Care and Use of Laboratory Animals, eighth
edition (2011) (http://grants.nih.gov/grants/
olaw/guide-for-the-care-and-use-of-laboratory-
animals.pdf). All institutional and national
guidelines for the care and use of laboratory
animals were followed.
RESULTS
Microfluidic Single-Islet Culture Setup
The precise dynamic perturbation of a
single-islet environment with the online
measurement of its response is prevented in
conventional culture systems, but can be
robustly achieved using microfluidic devices.
To this aim, we designed a microfluidic system
where a single islet can be trapped without
mechanical damage in a defined position,
dynamically stimulated with media of
multiple compositions, and contemporarily
observed under a microscope (Fig. 1a–c). Each
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islet was cultured under constant flow
perfusion, a condition that better mimics the
highly vascularized environment where islets
reside in vivo.
The microfluidic device includes an
integrated pneumatic valve system (Fig. 1b)
that is remotely controlled and enables
switching the medium entering the culture
chamber in few seconds, while minimizing
other culture perturbations (Fig. 1d). The time
required for the new medium to reach the islet
position within the channel was estimated
using buffer with or without fluorescein. At
the 2 ll/min flow rate used in all the
experiments, there was an approximate 50 s
lag between the medium valve switch and
medium change at the islet position (Fig. 1e).
The size and transparency of the microfluidic
device make possible the online microscopic
observation of the islet response. Overall, the
described setup provides maximal information
in terms of the spatial and temporal resolution
of the collected data.
Biological Validation of the Microfluidic
Device
The canonical glucose-stimulated insulin
secretion (GSIS) pathway in the b-cell fraction
of pancreatic islets involves some
well-established sequential steps: glucose is
transported into b-cells through plasma
membrane glucose transporters and is
metabolized, thereby elevating the
intracellular ATP/ADP ratio; this event causes
the closure of cell-surface ATP-sensitive K?
channels, leading to cell membrane
depolarization; plasma membrane
voltage-dependent Ca2? channels are
consequently opened, increasing cytosolic
Ca2? concentration and triggering the
exocytosis of insulin [28].
To interrogate islet behavior via microscopy,
we used multiple fluorescent dyes probing cell
viability and specific steps of GSIS pathway. We
added to the flowing culture media PE-labeled
Annexin V, a fluorophore for detecting early
apoptosis. We also loaded the islets, prior to
their insertion into the device, with dyes
enabling the detection of the intracellular
Ca2? concentration (Fluo-4 or Fura Red) and
cell membrane potential (Vf2.1Cl). We used
both confocal and two-photon microscopy.
After each islet insertion into the device, we
always observed its morphology to verify the
integrity of the external membrane (Fig. 2a, b;
Online Video 1). Islets that did not show a
visibly intact morphology, for example, due to
some variability in the extraction process, were
discarded. This occurred in less than 5% of the
cases and was usually associated with the
presence of some dead cells, assessed by
annexin V, not functionally responsive, for
instance in terms of intracellular Ca2?
oscillations under high-glucose stimulation
(Fig. 2c, d).
To verify that the microfluidic system did
not impair islet functional response, we
perfused the islets with high-glucose medium
(11 mM), which is stimulatory for insulin
secretion. We used islets from mutant mice
that express GFP under the insulin promoter in
order to identify the b-cells within the islet. In
Fig. 3a, we show persistent oscillations of the
intracellular Ca2? at 11 mM. As expected, the
oscillations were restricted to b-cells and were
not an artifact of the culture system or method
of analysis. Moreover, b-cells within the same
islet showed a properly synchronized response
(Fig. 3b).
To verify islet structural integrity also in
terms of cell–cell electrical coupling, we then
loaded the islets with Vf2.1Cl, a
voltage-sensitive fluorescent dye, and
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performed imaging at high speed. Under
high-glucose conditions, we were able to
observe the spatial propagation of membrane
potential waves throughout the islet (Fig. 3c;
Online Video 2), as previously reported [29].
As a last verification of functionality, we
loaded the islets with probes for detection of
both membrane potential and intracellular
Ca2?. Imaging at high speed, we observed the
two waves propagating at the same frequency,
but with a small delay of intracellular Ca2?
compared to membrane voltage (Fig. 3e, f;
Video 3). This result is consistent with Ca2?
regulation occurring along the pathway of
Fig. 2 Two-photon imaging of islet morphology and
viability in microﬂuidics. Islets were pre-loaded with
Hoechst 33342 and Fluo-4 for nuclear identiﬁcation and
intracellular Ca2? detection, respectively. Viability was
detected by adding annexin V in the ﬂowing medium. a,
b Images of single islets, intact (a) or subjected to
mechanical stress (b), within a microﬂuidic channel (see
video 1). From top left: morphology (transmitted light),
nuclei (blue), intracellular Ca2? (green), and mortality
(red). c, d Plots of intracellular Ca2? oscillations in the
same islets shown in a, b, respectively, constantly perfused
with buffer containing stimulatory glucose concentration
(11 mM). Zero-centered raw data. Annexin-V? cells from
the stressed islets do not display oscillatory Ca2? activity,
as detected by Fluo-4
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Fig. 3 Validation of islet functional response at 11 mM
glucose. a Green ﬂuorescence intensity of an islet isolated
from a Mouse Insulin Promoter (MIP)-GFP mouse,
pre-loaded with Fura Red for intracellular Ca2? detection.
b Plots of synchronous intracellular Ca2? oscillations of
cells in the regions of interest (ROIs) indicated in a. ROI 7
refers to non b-cells (GFP-), which do not show Ca2?
oscillatory activity in response to high glucose concentra-
tion. c Membrane potential of an islet from a wild-type
mouse loaded with the voltage dye Vf2.1.Cl and imaged at
the indicated time points during constant perfusion at high
glucose. The false-colored image sequence shows
ﬂuorescence intensity. d Plot of signal intensity inside
ROIs indicated in c. Oscillation phase shift describes the
spatial propagation of electrical activity from cell to cell
within the islet (see also Video 2). e Simultaneous
recording of intracellular Ca2? and membrane potential
in an islet from a wild-type mouse, pre-loaded with Fura
Red and Vf2.1.Cl. The false-colored image sequence shows
ﬂuorescence intensity. f Plot derived from data shown in
e. Intracellular Ca2? and membrane potential waves
propagate with the same periodicity. Ca2? propagation
occurs with slightly delayed phase (see also Video 3)
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insulin secretion and confirms that each step of
the pathway is in place and functional within
the microfluidic culture system.
Single-Islet Dynamic Stimulation
Next, we performed dynamic stimulations of
the islets, fully taking advantage of the
developed microfluidic setup that makes
automatically switching between media of
different compositions possible. For these
experiments, we also added a cell-impermeant
Zn2?-sensitive fluorophore (FluoZin-3) to the
flowing culture media. Zn2? measurement was
used to indirectly evaluate the dynamics of
insulin secretion, as Zn2? is present within the
intracellular insulin-containing granules
undergoing exocytosis [30].
We analyzed single-islet response both upon
switching between non-stimulatory (3 mM) and
stimulatory (11 mM) glucose concentrations
and in the presence of tolbutamide, an
ATP-sensitive K?-channel blocker that induces
insulin secretion even at non-stimulatory
glucose concentrations [31]. As expected,
tolbutamide produced a sudden increase of
insulin secretion (Fig. 4a; Online Video 4) and
of intracellular Ca2? concentration (Fig. 4b).
Altogether, these data demonstrate islet
functionality within the microfluidic system,
validate the detection method for analyzing
single islets with high spatio-temporal
resolution in response to stimulations, and
give a demonstration of the high potential of
this system for performing accurate dynamic
studies.
Effects of Simvastatin on Insulin Secretion
In a previous study on MIN-6, a murine
insulinoma cell line, simvastatin was shown to
reduce insulin secretion by targeting
ATP-sensitive K?-channels, voltage-gated
Ca2?-channels, muscarinic M3 receptors, and
GPR40 in a time span of approximately an hour
[13]. On a shorter time scale (minutes), the
same study demonstrated that simvastatin
suppresses cytosolic Ca2? regulation in
response to both stimulatory glucose
concentrations and tolbutamide in MIN-6 cells.
We used our validated microfluidic system to
analyze short-term effects of simvastatin on the
insulin secretion pathway using intact single
Fig. 4 Physiologic and pharmacologic validation of islet
functionality. a The islet shown in the inset was
dynamically perfused with different media, as indicated,
all containing the FluoZin-3 Zn2?-sensitive ﬂuorophore.
This dye indicates Zn2? secretion from the islet, as an
indirect measurement of insulin secretion [21]. The plot
shows changes of ﬂuorescence intensity in the ROI shown
in the inset. The false-colored images at the bottom show
the spatial ﬂuorescence intensity at different time points
(see Video 4). b The islet shown in the inset was
pre-loaded with FuraRed and dynamically perfused with
different media, as indicated. Fluorescence intensity in the
inset ROI was quantiﬁed in the plot that shows intracel-
lular Ca2? concentration
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pancreatic islets as a more physiologically
relevant in vitro model.
After testing different concentrations of
simvastatin from 1 to 10 lM (data not shown),
we used a 1 lM concentration in all
experiments, as the lowest concentration of
drug that elicited an effect on islet function. We
then analyzed the ability of simvastatin to
modify insulin secretion by single islets in
microfluidics. As shown in Fig. 5a and Online
Video 5, simvastatin rapidly blocked insulin
secretion even in the presence of a stimulatory
glucose concentration (11 mM). The same
inhibitory effect on secretion was observed
independently of the sequence in which
stimuli were applied (Fig. 5a, b). Such a rapid
and reversible effect of simvastatin on single
islets has never been shown before and was
detected taking advantage of the small-scale
transparent dynamic setup we developed.
To compare our data to those previously
obtained with MIN-6 cells, we coupled the
measurement of insulin secretion with that of
cytosolic Ca2?. Unlike in Yaluri et al. [13], we
found that cytosolic Ca2? was not affected by
simvastatin in single islets, despite its inhibition
of insulin secretion at stimulatory glucose
concentrations (Fig. 6a; Online Video 6). This
suggests that simvastatin acts on the late stages
of insulin granule trafficking, downstream of
cytosolic Ca2? regulation. However, when
tolbutamide was concomitantly used to induce
insulin secretion, simvastatin did not prevent a
cytosolic Ca2? increase and insulin secretion, at
both low (3 mM) and high (11 mM) glucose
concentrations (Fig. 6b). Similarly, islet
treatment with simvastatin, prior to addition
of tolbutamide, did not prevent the rise in
cytosolic Ca2? concentration and insulin
secretion (Fig. 6c).
DISCUSSION
In this study, we developed and validated a
microfluidic platform optimized for functional
analysis of single pancreatic islets by live
confocal and two-photon imaging.
Microfluidic systems are increasingly used to
study physiological phenomena in vitro, with
several advantages [32, 33]. The possibility to
analyze a single islet, the fundamental unit of
endocrine pancreas, preserves intercellular
Fig. 5 Effects of simvastatin on glucose-induced insulin
secretion. a Dynamics of insulin secretion, indirectly
measured by FluoZin-3 ﬂuorescence intensity, during islet
perfusion with media of different compositions, as indi-
cated. b Same as a, inverting the order of simvastatin
stimulation at high-glucose concentration
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interactions within the islet and avoids the
confounding complexity of whole animal
physiology and inter-islet communication as
in organo-culture. By using a miniaturized
multichannel system we could remotely
control the switch of the perfusion medium
entering the microfluidic chamber with a
resolution of seconds and analyze live how a
single islet responds to different exogenous
stimuli. In vivo imaging of the endocrine
pancreas is the most suitable physiological
model to assess insulin secretion. However,
this is poorly standardized, highly invasive,
and laborious. In particular, it is difficult to
deliver precisely localized stimuli, while
dynamically visualizing b-cell response. Ex
vivo intact islets are fully functional units,
whereas b-cell lines are immortalized and
often not pure: the commonly used MIN6 cell
line contains a mix of pancreatic endocrine cells
[34]. Furthermore, primary islets can be quickly
isolated and immediately used for imaging,
whereas b-cell lines are difficult to maintain in
culture (Table 1).
Using confocal and two-photon imaging, we
showed normal functionality of single islets
within the microfluidic device in terms of
synchronized membrane voltage and
intracellular Ca2? regulation, as well as
glucose- and tolbutamide-stimulated insulin
secretion.
As a clinically relevant application of this
setup, we explored the effects of the HMG-CoA
reductase inhibitor, simvastatin, on Ca2?
dynamics and insulin secretion. Several reports
suggest that statins may increase the risk of
developing diabetes by acting on insulin
secretion, insulin resistance, or both
[11, 12, 35, 36]. However, whether statins
truly inhibit insulin secretion is unclear.
Pooling together five murine islets,
Zu´n˜iga-Hertz et al. demonstrate that
simvastatin interferes with isoprenylation of
proteins involved in insulin granule exocytosis
on a 2-h time scale and with cholesterol
biosynthesis on a 24-h time scale [14]. Shorter
time effects of simvastatin on the GSIS pathway
have only been demonstrated in vitro using a
Fig. 6 Effects of simvastatin on insulin secretion and
intracellular Ca2? concentration at 11 mM glucose.
a–c Plots show the simultaneous recording of FluoZin-3
and Fura Red ﬂuorescence intensity of islets pre-loaded
with Fura Red and perfused with media of different
compositions, as indicated
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murine b-cell line, MIN-6, and only as for its
action on cytosolic Ca2? dynamics [13].
Here, we extended the results previously
obtained with MIN-6 cells to single, freshly
isolated murine islets. While Yaluri et al. [13]
found that simvastatin affects Ca2? regulation,
in our results single islet cytosolic Ca2? is not
perturbed by simvastatin. Moreover, for the first
time, we were able to demonstrate that
simvastatin affects insulin secretion of single
islets, a result previously shown only by pooling
more islets together, a less physiological model
because of the in vivo islet–islet coordination
[37], and analyzing insulin secretion only on
much longer time scales. The rapidity of the
simvastatin effect on insulin secretion suggests
its involvement in regulatory mechanisms
other than cholesterol biosynthesis and
post-translational modifications, which require
more time to occur.
Ultimately, we showed that single islets
respond to simvastatin acutely and reversibly,
blocking the normal insulin secretion induced
by high glucose. As there is no effect of
simvastatin on Ca2? intracellular
concentration and dynamics, we suggest that
the inhibitory effect on insulin secretion may be
exerted at the levels of insulin granule
trafficking. Moreover, tolbutamide can
effectively counteract the inhibitory effect of
simvastatin on insulin secretion, suggesting
that simvastatin’s action is reversible not only
by its withdrawal, but also by Ca2? overload and
membrane depolarization. Reversibility of the
effect has clinical implications and likely
reflects the relatively benign effect of statins
Table 1 A comparison of different models for beta cell imaging
Methods Usefulness Limitation
Cell line Controlled experimental conditions
Reproducibility
Difﬁcult to maintain in culture
Immortalized
No pure beta cell line (e.g., MIN6)
No interaction with alpha/delta cells
Pooled islet culture Controlled experimental conditions
Quick isolation (2 h)
Preserved islet heterogeneity integrity
High signal-to-noise ratio
Batch-to-batch variability
3 days of vitality after isolation
Average response from asynchronous islets
Intact single islet Controlled experimental conditions
Quick isolation (2 h)
Preserved islet heterogeneity integrity
Quasi-physiological model
3 days of vitality after isolation
Islet-to-islet variability
Animal model High-ﬁdelity physiological model Difﬁcult visualization
No controlled conditions
High variability
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on diabetes onset or progression. Limitations of
this study are inherent to the short time course
of observation and the lack of a dose-dependent
response. Table 2 highlights the advancement
over the state of the art made by our study.
CONCLUSION
In conclusion, we report that simvastatin
rapidly and reversibly impairs insulin release
from intact islets ex vivo. Further work is
needed to understand the underlying
mechanisms of action of simvastatin at the
second-to-minute scale. The microfluidic and
imaging techniques herein described will be
suitable to dissect the molecular and
electrophysiological processes underlying this
statin effect. The possibility to use concomitant
treatments will help to clarify whether the effect
of simvastatin can be counteracted by other
glucose-lowering agents with mechanisms of
action different from sulfonylureas, such as
GLP-1 receptor agonists or even SLGT2
inhibitors.
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What was previously
known?
Clinical trials and epidemiological studies suggest that statins increase the risk of developing
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In vitro studies show that statins impair insulin secretion by affecting multiple pathways,
including cellular cholesterol synthesis, membrane ﬂuidity, and isoprenylation of proteins
What this study adds? We have used a new methodological approach to dynamically study the inhibitory effect of
simvastatin on insulin secretion of intact islets. Data show this effect is rapid and reversible
What are the
implications?
Rapidity of inhibition suggests mechanisms unrelated to cholesterol synthesis, but possibly based
on electrophysiology or granule docking/fusion modulation
Reversibility of inhibition has clinical implications and may suggest a relatively benign effect of
statins on beta cell function
Which are the next
steps?
To better dissect the molecular mechanisms of insulin secretion inhibition by statins
To identify concomitant treatments that may counteract the effects of statins on insulin secretion
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study. The protocol followed the Guide for the
care and use of laboratory animals, Eighth
edition (2011) (http://grants.nih.gov/grants/
olaw/guide-for-the-care-and-use-of-laboratory-
animals.pdf). All institutional and national
guidelines for the care and use of laboratory
animals were followed.
Data Availability. The datasets used during
and/or analyzed during the current study are
available from the corresponding author on
reasonable request.
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in any medium, provided you give appropriate
credit to the original author(s) and the source,
provide a link to the Creative Commons license,
and indicate if changes were made.
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